Does Rallies show 13F holders for INM?

Yes. Rallies tracks hedge fund and 13F ownership data for INM, including fund names, share counts, latest tracked quarter, and position changes when available.

Is INM research on Rallies investment advice?

No. Rallies provides research, data, and educational context for INM. It does not provide personalized investment advice.

INM (InMed Pharmaceuticals Inc. Common Shares) Stock Analysis - Hedge Fund Holdings

InMed Pharmaceuticals Inc. Common Shares (INM) is a publicly traded Healthcare sector company. As of May 19, 2026, INM trades at $1.42 with a market cap of $2.12M and a P/E ratio of -0.08. INM moved +125.50% today. Year to date, INM is -39.22%; over the trailing twelve months it is -76.93%. Its 52-week range spans $0.58 to $8.27. Rallies surfaces INM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns INM stock?

Hedge funds tracked by Rallies that own INM include Citadel Advisors, Renaissance Technologies, and Two Sigma. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for InMed Pharmaceuticals Inc. Common Shares.

INM Key Metrics

Key financial metrics for INM
Metric	Value
Price	$1.42
Market Cap	$2.12M
P/E Ratio	-0.08
EPS	$-8.36
Dividend Yield	0.00%
52-Week High	$8.27
52-Week Low	$0.58
Volume	70.34M
Avg Volume	0
Revenue (TTM)	$4.94M
Net Income	$-8.16M
Gross Margin	34.53%

Top Hedge Funds Holding INM

Citadel Advisors holds 56.67K shares of INM, changed +368.43% as of Sep 30, 2024.
Renaissance Technologies holds 50.30K shares of INM, changed +77.72% as of Sep 30, 2024.
Two Sigma holds 15.42K shares of INM, changed +19.61% as of Mar 31, 2024.

Latest INM News

InMed-Mentari Merger Secures US$290M, Funds Migraine Programs Through 2028 — May 19, 2026
InMed Slashes Preferred Option Strike Price to $0.80 for 278,761 Shares — May 19, 2026
InMed Reports Q3 $3.0M Loss and Preclinical Data for Alzheimer’s Drug — May 6, 2026
InMed slashes exercise prices to $0.80 on 2.3M preferred options — Apr 27, 2026
InMed Notified of Sub-$1 Bid Price, Faces 180-Day Compliance Deadline — Mar 27, 2026

Recent INM Insider Trades

MANCINI ALEXANDRA DIANE JANET sold 240 (~$42.312) on Jul 31, 2024.
HULL ANDREW bought 37.50K (~$14.63K) on Feb 21, 2024.
ADAMS ERIC A bought 41.60K (~$14.92K) on Feb 20, 2024.

INM Analyst Consensus

INM analyst coverage data. Average price target: $0.00.

Common questions about INM

Who owns INM stock?: Hedge funds tracked by Rallies that own INM include Citadel Advisors, Renaissance Technologies, and Two Sigma. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for InMed Pharmaceuticals Inc. Common Shares.
Does Rallies show 13F holders for INM?: Yes. Rallies tracks hedge fund and 13F ownership data for INM, including fund names, share counts, latest tracked quarter, and position changes when available.
Is INM research on Rallies investment advice?: No. Rallies provides research, data, and educational context for INM. It does not provide personalized investment advice.